Counseling for Opioid Use Disorder in Cherokee Nation
This study is testing a program called CHaRRM-CN to improve care for Opioid Use Disorder (OUD) in the Cherokee Nation. It compares CHaRRM-CN, which adds culturally relevant activities like Talking Circles and beading to standard treatment, with "treatment as usual" (TAU). TAU includes medication like buprenorphine + naloxone (Suboxone gel films), case management, and counseling. The study wants to see if CHaRRM-CN helps people stay in treatment longer, reduces drug use and harm, and increases connection to their culture. You might be able to join if you are at least 18 years old and have recently started or are rejoining the Cherokee Nation Health Services MAT Program. The study is currently unclear on its recruitment status and plans to enroll 136 participants.
- Study design
- This is an interventional, randomized study comparing two different treatment approaches for Opioid Use Disorder. It plans to enroll 136 participants.
- What's involved
- After giving written consent, you will have a baseline assessment and then be assigned to either the CHaRRM-CN or treatment as usual group for 6 months. You will also attend follow-up appointments at 1, 3, and 6 months to track your progress.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months after randomization, with follow-up visits at 1, 3, and 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Lonnie A Nelson, PhD · PRINCIPAL_INVESTIGATOR · Washington State University
- Susan E Collins, PhD · PRINCIPAL_INVESTIGATOR · University of Washington
- Ashley Lincoln, MSW · PRINCIPAL_INVESTIGATOR · Cherokee Nation Health Services
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- MAT retentionMonth 6
MAT program retention is defined by an active prescription for buprenorphine+naloxone with no gaps ≥ 30 days at month 6. This measure will dichotomously indicate whether participants have been retained in the MAT program (1) or not (0) at month 6.